The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated results from phase 1b/2 ELECTRA and ELEVATE clinical studies evaluating elacestrant in combination with other treatments.
May 23, 2024
· 9 min read